Abstract
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a bioactive peptide known for its diverse effects on the nervous system. While numerous studies have demonstrated the neuroprotective properties of PACAP, its role in tissue regeneration and potential as a therapeutic agent remain to be fully understood. Specifically, the understanding of PACAP’s impact on cytoskeletal dynamics, particularly the organization and disorganization of actin filament networks, is limited due to the scarcity of in vitro studies in this area. Additionally, the interaction between PACAP and actin has been minimally explored, and the influence of PACAP on the thermal stability of actin is completely unknown. To address these gaps, the current study aimed to investigate the impact of different forms and fragments of PACAP on the thermal denaturation and renaturation of Ca2+-G-actin using a differential scanning calorimetry (DSC) approach. Our primary objective was to determine whether PACAP modulates the thermal stability of Ca2+-G-actin and establish a temperature-dependent pattern of any structural alterations that may occur as a result of PACAP interaction. Two PACAP forms exist in vivo: the 38 amino-acid length PACAP38 and the PACAP27, the latter truncated at the C-terminal. In the PACAP38 + Ca2+-G-actin mixture, the DSC scans exhibited a mild decrease in actin denaturation temperature compared to the control, plus an exotherm appeared in the high-temperature range with a significantly increased calorimetric enthalpy. The truncated PACAP27 produced a slight increase in actin denaturation temperature with the same exotherm without significant alteration in enthalpy. In PACAP6-38 mixture (i.e., an artificial fragment of PACAP38 + Ca2+-G-actin), there was no change in the denaturation temperature of actin and no plus exotherm, but significant ΔHcal was observed. With the modified PACAP6-27 (another artificial fragment), the exotherm was absent, but the actin denaturation temperature and enthalpy increased compared to the control. Through this research, we sought to elucidate the underlying mechanisms of PACAP’s effects on actin dynamics and provide valuable insights into the potential therapeutic applications of PACAP in the context of cytoskeletal organization and neuronal regeneration. The findings of this study may contribute to the development of novel strategies targeting actin-related processes for neuroprotection and neural tissue repair.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a neuropeptide with wide distribution in the nervous system [1, 2]. It was first discovered in the hypothalamus, where it was found to activate cyclic adenosine monophosphate in anterior pituitary as well as it stimulates the release of pituitary hormones [3]. PACAP potently induces cyclic adenosine monophosphate (cAMP) levels in anterior pituitary cells as well as it stimulates the release of pituitary hormones. PACAP has two biologically active forms consisting of 38 amino acids (PACAP38) and 27 amino acids (PACAP27). The PACAP38 is the dominant form which undergoes internal cleavage-amidation resulting in the PACAP27 fragment [4,5,6]. PACAP is considered to be a member of the VIP/secretin/glucagon superfamily [4, 6, 7], and it shares structural similarities with vasoactive intestinal polypeptide (VIP) [8, 9]. The potent antagonist form of PACAP is residues 6–38 [10]. PACAP is synthesized as a precursor protein and is then cleaved to generate the active peptide. PreproPACAP is the precursor protein that contains a signal peptide. This signal peptide is cleaved to generate proPACAP, which is then further processed to produce the active peptide, PACAP.
PACAP binds to three G protein-coupled receptors, PAC1, VPAC1, and VPAC2. PAC1 is the most widely distributed of these receptors and plays an important role for mediating the effects of PACAP. The VPAC1 and VPAC2 receptors are also activated by VIP with similar affinity [11,12,13,14,15,16,17,18,19,20].
PACAP has a wide range of physiological actions. Among others, PACAP is involved in the regulation of pituitary hormone release [21, 22], the control of cardiovascular function [23], and the modulation of neuronal activity in the central and peripheral nervous systems [24, 25]. It has a well-known neurotrophic, neuroprotective and general cytoprotective effects based on its anti-inflammatory, antioxidant and anti-apoptotic properties. PACAP and its receptors are widely expressed in the nervous system, and they are involved in the regulation of neurogenesis, neuronal development and cell differentiation [26,27,28,29,30,31,32,33].
In previous investigations in cerebellar granule cells [34, 35], researchers reported contrasting effects of PACAP and ceramides on cellular migration, neurite outgrowth, and cytoskeletal remodeling, attributed to their opposing influences on actin distribution, tubulin polymerization, and Tau phosphorylation. To elaborate, C2-ceramide was associated with disrupted actin filament organization, tubulin depolarization, and altered microtubule-associated protein Tau, concomitant with impaired cell motility and neurite outgrowth. Conversely, PACAP exhibited a strengthening effect on actin polymerization at the growth cone, increased Tau phosphorylation, and counteracted the cytoskeletal perturbations induced by C2-ceramide. Furthermore, regarding actin and tubulin distribution and expression, PACAP treatment independently promoted actin polymerization at the growth cone, whereas it did not elicit remarkable alterations in tubulin cellular distribution. These previous findings highlight the distinct and opposing regulatory roles of PACAP and C2-ceramide in modulating critical aspects of cytoskeletal dynamics and cellular behavior.
Numerous in vivo animal models proved its neuroprotective effects. It has been discovered to protect neurons from oxidative stress, ischemia and different neuronal injuries [31,32,33]. Endogenous PACAP can also predict the outcome/mortality of patients who suffered traumatic brain injury [36, 37]. PACAP has been proposed as a therapeutic target for several neurological and psychiatric disorders, including Parkinson’s disease [38, 39], Alzheimer’s disease [39, 40], depression [41], and anxiety [42]. However, more research is needed to fully understand the therapeutic potential of PACAP and to develop effective PACAP-based therapies.
Aims of this study
The cytoskeleton, a dynamic network of structural proteins, plays a pivotal role in maintaining cellular shape, supporting intracellular transport, and facilitating cell movement. Among its key components, actin filaments stand out as major determinants of cytoskeletal architecture and function. Understanding the regulatory mechanisms governing actin dynamics is crucial for deciphering fundamental cellular processes.
While numerous studies have demonstrated the neuroprotective properties of PACAP, its role in tissue regeneration and potential as a therapeutic agent remains to be fully understood. Specifically, the understanding of PACAP’s impact on cytoskeletal dynamics, particularly the organization and disorganization of actin filament networks, is limited due to the scarcity of in vitro studies in this area. Additionally, the interaction between PACAP and actin has been minimally explored [34, 35], and the influence of PACAP on the thermal stability of actin is completely unknown. To build upon our understanding of PACAP's intricate interplay with the cytoskeleton, particularly actin dynamics, we employed differential scanning calorimetry (DSC) to investigate the thermodynamic aspects of PACAP–actin interactions.
In this context, our study focuses both on PACAP and its interactions with actin. Despite its potential therapeutic applications, the intricate interplay between PACAP and the cytoskeleton, especially actin, remains largely unexplored. Therefore, our research seeks to unravel the effects of PACAP on actin dynamics, shedding light on its significance in cytoskeletal regulation. Through a comprehensive investigation utilizing differential scanning calorimetry (DSC), we aim to elucidate the temperature-dependent alterations in Ca2+-G-actin stability induced by various forms and fragments of PACAP (see Fig. 1). Unveiling these interactions holds great promise for advancing our understanding of cytoskeletal biology and potentially paving the way for novel neuroprotective strategies.
Materials and methods
Actin preparation
Ca2+-G-actin was prepared from rabbit striated muscle using a well-established protocol in our lab [43,44,45]. The MoPS buffer, essential for actin extraction and stabilization, was composed of MoPS(3-(N-morpholino) propane sulfonic acid) as the buffering agent, CaCl2 to maintain calcium ions at physiologically relevant levels, MEA (β-mercaptoethanol) as a reducing agent, and NaN3 to prevent bacterial contamination. Additionally, the buffer was supplemented with ATP (adenosine triphosphate) to maintain actin in its active state. The actin preparation also involved the inclusion of 50 mM KCl and 2 mM MgCl2 to support proper actin stability throughout the experiments. Rigorous care was taken to ensure the purity and integrity of the Ca2+-G-actin sample, thus guaranteeing the reliability and accuracy of subsequent investigations into the effects of PACAP on actin dynamics. We set the pH of the buffer at 7.8 which is essential to create a biologically relevant and controlled environment for studying actin dynamics and its interactions with PACAP. This approach ensures the stability of actin, increases the reliability of experimental results, and facilitates the understanding of how PACAP influences cytoskeletal regulation under conditions closely resembling those found in living systems. Purity of G-actin was verified by absorption photometry (clean peak at 280 nm) and by polyacrylamide gel electrophoresis (PAGE).
PACAP
For the applied PACAP forms and fragments and their amino acid sequences please check Fig. 1.
Differential Scanning Calorimetry (DSC) Measurements
The thermal unfolding experiments were performed by SETARAM Micro DSC-III in the 0–110 °C temperature range with 0.3 K min−1 scanning rate during two heating/cooling cycles. Conventional Hastelloy batch vessels were used during the denaturation experiments with 950 μL sample volume on average. (Conventional Hastelloy batch vessels are containers made of Hastelloy, a type of corrosion-resistant alloy composed mainly of nickel, chromium, and molybdenum. These vessels are commonly used in differential scanning calorimetry (DSC) experiments to hold the sample material and reference material during the measurement process. Hastelloy is chosen for its durability and resistance to corrosion, ensuring that the vessel does not react with the substances being analyzed, thereby preserving the integrity of the samples and providing accurate results in DSC experiments.) High-pressure pans and covers were utilized to maintain a sealed environment for the samples throughout the experiment, ensuring the integrity of the measurements and preventing any external influences on the samples during the differential scanning calorimetry (DSC) analysis.
The reference sample was the MoPS buffer. The sample and reference samples were equilibrated with a precision of ±0.1 mg. The buffer–buffer set was used as a baseline reference, which was subtracted from the original DSC curve. We have plotted the heat flow (DSC-III is a heat flux instrument with hermetically closed vessels) in the function of temperature. Calorimetric enthalpy was calculated from the area under the heat flow curve by using a two-point setting SETARAM peak integration. All results are given in mean values ± standard error (s.d., three measurements were performed in all cases).
For the assessment of thermal stability and interactions, Ca2+-G-actin was utilized at a consistent concentration of 2 mg mL−1 in all experiments. This concentration ensured the proper methodological conditions for DSC and allowed for meaningful comparisons across the experimental setup. As for the PACAP peptide, it was employed at a concentration of 21 µM, providing an optimal range for investigating potential interactions with actin under controlled experimental conditions. DSC measurements were performed with a highly sensitive calorimeter, enabling precise evaluation of the thermal denaturation and renaturation of Ca2+-G-actin in the presence of PACAP. The use of these standardized concentrations allowed for robust and reproducible data acquisition, facilitating a comprehensive understanding of PACAP's impact on actin stability and possible cytoskeletal regulation.
Results
In Fig. 2 and Table 1, the summarized result of the denaturation measurements of the physiologically important PACAP compounds can be seen in two heating–cooling cycles. The baseline reproducibility of our DSC is about ~ 2–3 µW, so we have to make more tests to check the reality of those scans that are lying close to this range. PACAP38 exhibited two endotherms at first heating around 40 and 57 °C and an exotherm at 91 °C. During the first cooling, we did not observe a detectable effect, which was surprising. However, in the second heating, the low-temperature denaturations were eliminated (indicating an irreversible change after the first heating), and the exotherm shifted to a higher value (~101 °C). The PACAP27 produced no endotherms but two exotherms in the first heating. During the second heating the first disappeared, but the second one remained at the same temperature with nearly the same ΔH. All effects were in the range of instrument error. These two derivatives should have a very stable core from a thermal point of view, which is supported by its interaction with G-actin (see Fig. 3 and Table 2).
In Fig. 3, the summarized result of the denaturation measurements can be seen performed on Ca2+-G actin mixed with PACAP compounds having physiologically relevant concentration. The Ca2+-G actin exhibited only a usual denaturation peak (Tm) around 56 °C with 0.023 Jg−1 calorimetric enthalpy (ΔHcal) [46].
The denaturation of Ca2+-G actin alone was irreversible, we did not detect a thermal signal either during the first cooling or during the second heating and cooling. In addition to Ca2+-G actin as the active form of PACAP [47], it shifted the transition temperature down to 55.7 °C, and at ~ 57 °C appeared a shoulder in the scan in case of first heating. This latter refers to the fading of the interaction between the two major domains of G-actin, which is a consequence of the binding of PACAP38 to the nucleotide-binding pocket of G-actin. We did not observe this strong effect for the other PACAP forms, which may emphasize a higher physiological importance of PACAP38. The whole denaturation temperature range decreased by ~ 4 °C, and at 98.7 °C appeared an exotherm with about half ΔHcal compared to the main denaturation (see Table 2). The cooling effect should be further investigated because it falls into the range of error of enthalpy detection of the instrument. The raw measurement data were smoothed by software, because a small effect is difficult to distinguish from the "base noise" of the instrument. These smoothed DSC curves show the tendency for a renaturation process. We need additional, more measurements so that averaging can reduce the role of noise, proving the fact of renaturation.
During the second heating, the actin signal disappeared (irreversibly denatured), and the exotherm exhibited lower Tm and at least a 40% smaller calorimetric enthalpy. This should be a PACAP signal, but its identification needs further investigation (see Fig. 2 and Table 1).
The PACAP27 fragment produced also an endotherm and exotherm. The endotherm’s Tm was a bit higher than in the case of PACAP38 with the same ΔHcal, but the exotherm exhibited 2.5 times higher calorimetric enthalpy during the first heating compared with PACAP38, while Tm remained practically the same. During the second heating, the endotherm was also absent, the exotherm peak decreased significantly producing closely the same ΔHcal as in the case of first heating (see Fig. 3 and Table 2).
The PACAP6-38 fragment exhibited nearly the same Tm but by 60% higher ΔHcal as was detected in the case of the Ca2+-G actin alone, without exotherm. The second heating cycle gave no detectable thermal effect because the DSC signal was in the range of instrument baseline fluctuation, that is the Ca2+-G actin PACAP6-38 complex underwent irreversible denaturation. This result is not shown in any figures or tables.
The first DSC scans of PACAP6-27 produced the same basic effect as was observed at PACAP6-38, but the Tm was the highest in our experiments with the smallest ΔHcal among the investigated complexes (see Fig. 3 and Table 2).
In line with prior in vitro studies [34, 35], our investigation has confirmed that PACAP exerts a substantial influence on the (thermal) stability of actin monomers, resulting in remarkable alterations in actin's structural and denaturation characteristics, potentially leading to functionally significant conformational changes. Nevertheless, a comprehensive exploration of these effects warrants further in-depth research.
Discussion
In this study, we conducted a comprehensive investigation on the effects of various PACAP fragments on the thermal stability of Ca2+-G actin using differential scanning calorimetry, and we also investigated the thermal stability of these PACAP forms and fragments alone (without Ca2+-G actin).
The DSC experiments conducted on physiologically relevant PACAP compounds in the absence of actin revealed intriguing thermal profiles. These findings suggest that both PACAP38 and PACAP27 possess a remarkably stable core (very likely that the red and green parts of the structure (see Fig. 1) are responsible for the exotherm process, while the missing red part is responsible for the absence of endotherm transition) from a thermal perspective, as evidenced by their resistance to denaturation and the observed interactions with G-actin. The presence of multiple thermal transitions implies complex structural changes or conformational rearrangements within these PACAP molecules. Further investigation is warranted to elucidate the precise nature and functional significance of these thermal transitions and their potential roles in biological processes because the PACAP molecules alone produced mild thermal effects in the investigated temperature range.
Regarding PACAP–actin complexes, our results demonstrated that Ca2+-G actin itself exhibits a typical denaturation peak, and the denaturation was irreversible, suggesting a significant structural alteration during this process. The addition of the active form of PACAP [47] to Ca2+-G actin induced a mild decrease (0.4 °C) in the denaturation temperature in the case of first heating, which could be a sign of loosening of the globular actin structure, because of the binding of PACAP into the cleft of actin. The exotherm effect at ~ 99 °C with relatively high ΔHcal (see Table 2) should refer to an aggregation of non-bound PACAP molecules. During the second heating, only the PACAP effect was detected with a significantly smaller peak temperature and ΔHcal, as in the case of a single PACAP sample. The first and second cooling produced an effect in the error range of the instrument, so we neglected it.
In the case of the PACAP27 fragment during the first heating cycle, the exotherm exhibited a significantly higher calorimetric enthalpy compared to PACAP38 (despite similar Tm values), which indicates more complex structural changes and greater ordering of the complex. This difference highlighted the unique thermodynamic behavior of PACAP27. In the case of the PACAP27-actin complex, this could imply that it undergoes more intricate or extensive conformational changes during heating compared to the PACAP38-actin complex. These changes may involve, initiating a larger number of bonds or interactions among PACAP molecules. This way higher ΔHcal can indicate greater overall stability of the complex. In other words, the complex might be held together by stronger forces or a higher number of interactions. This could mean that the PACAP27-actin complex has greater overall stability compared to the PACAP38-actin complex. During the second heating, the final stability of PACAP27 remained similar to the first heating result. The cooling phases should be also checked by performing more experiments or using different concentrations, because of the very low measured data.
Our results reveal that the PACAP6-38 and PACAP6-27 fragments, while exhibiting a denaturation temperature (Tm) similar to that of Ca2+-G actin alone, displayed a substantially higher calorimetric enthalpy, indicative of increased energy requirements for structural changes during denaturation. Importantly, the absence of an exothermic signal suggests a distinct denaturation process, highlighting the unique thermodynamic behavior of the PACAP6-38-actin and PACAP6-27-actin complexes.
In conclusion, it is the first attempt to investigate the actin-PACAP interaction with a thermoanalytical method. This way our study underscores the complex interplay between both natural PACAP forms [27, 47] and actin, revealing distinct thermodynamic profiles associated with different PACAP fragments. The notable shift observed when PACAP was added to Ca2+-G actin definitely indicates that the interaction between PACAP and actin alters the thermal stability of the actin. This shift can have important implications for understanding how PACAP influences the structure and stability of actin filaments, which are crucial components of the cytoskeleton and play essential roles in various cellular processes, including cell movement and shape maintenance. Our experimental findings obviously demonstrated that PACAP exerts a noticeable thermodynamic influence on the thermal stability and denaturation behavior of Ca2+-G actin. Notably, among the PACAP variants investigated, full-length PACAP (PACAP38), which is known for its substantial physiological regulatory activity alongside PACAP27, exhibited the most pronounced effect on actin thermal stability. Additionally, our study revealed that other examined PACAP forms and fragments (PACAP27, PACAP6-38, PACAP6-27) also induced alterations in the thermal stability profile of Ca2+-G actin, albeit to a lesser degree. These findings collectively underscore the various interactions between PACAP and actin, offering valuable insights into their thermodynamic behavior.
Our study also suggests that the complex formation between PACAP and actin is not merely an additive effect of their individual properties but involves specific interactions that modify the overall stability of the system. Further investigation is needed to precisely characterize these interactions and their functional consequences performing more experiments.
Conclusions
In conclusion, this study represents a pioneering effort to investigate the interaction between PACAP and G-actin using a thermoanalytical approach. The findings reveal distinct thermodynamic profiles associated with different PACAP fragments, emphasizing the complex interplay between PACAP forms [27, 47] and actin. The observed shift in thermal stability upon the addition of PACAP to Ca2+-G actin underscores the significant influence of PACAP on actin's structure and stability. Specifically, full-length PACAP (PACAP38) exhibits the most pronounced effect on actin thermal stability, highlighting its physiological regulatory activity alongside PACAP27. Additionally, other PACAP forms and fragments (PACAP27, PACAP6-38, PACAP6-27) induce alterations in the thermal stability profile of Ca2+-G actin, albeit to a lesser extent.
Furthermore, our results suggest that the complex formation between PACAP and G-actin involves specific interactions that modify the overall stability of the system, extending beyond a simple additive effect of their individual properties. The intricate thermodynamic behavior observed, including multiple thermal transitions and changes in calorimetric enthalpy, underscores the complexity of the PACAP-actin interaction and its potential implications for cellular processes such as cell movement and shape maintenance. However, further investigation (mainly PACAP interactions with F-actin) is warranted to precisely characterize these interactions and understand their functional consequences, necessitating additional experiments and analyses. Overall, this study provides valuable insights into the thermodynamic dynamics of the PACAP-actin interaction, laying the groundwork for future research in this field.
Availability of data and materials
There are no additional available data to upload.
References
Miyata A, Jiang L, Dahl RD, Kitada C, Kubo K, Fujino M, et al. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun. 1990;170:643–8.
Ohkubo S, Chiharukimura, Ogi K, Okazaki K, Masakihosoya, Okazaki H, et al. Primary structure and characterization of the precursor to human pituitary adenylate cyclase activating polypeptide. DNA Cell Biol. 1992;11:21–30.
Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun. 1989;164:567–74.
Wang J, Song X, Zhang D, Chen X, Li X, Sun Y, et al. Cryo-EM structures of PAC1 receptor reveal ligand binding mechanism. Cell Res. 2020;30:436–45.
Hamelink C, Lee H-W, Chen Y, Grimaldi M, Eiden LE. Coincident elevation of cAMP and calcium influx by PACAP-27 synergistically regulates vasoactive intestinal polypeptide gene transcription through a novel PKA-independent signaling pathway. J Neurosci. 2002;22:5310–20.
Handbook of Biologically Active Peptides [Internet]. [cited 2022 Dec 28]. Available from: https://www.nhbs.com/handbook-of-biologically-active-peptides-book-2
Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev. 2009;61:283–357.
Sherwood NM, Krueckl SL, McRory JE. The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev. 2000;21:619–70.
Lelièvre V, Pineau N, Du J, Wen C-H, Nguyen T, Janet T, et al. Differential effects of peptide histidine isoleucine (PHI) and related peptides on stimulation and suppression of neuroblastoma cell proliferation: a novel VIP-independent action of PHI via map kinase. J Biol Chem. 1998;273:19685–90.
Sun C, Song D, Davis-Taber RA, Barrett LW, Scott VE, Richardson PL, et al. Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS. Proc Natl Acad Sci. 2007;104:7875–80.
Langer I. Conformational switches in the VPAC1 receptor. Br J Pharmacol. 2012;166:79–84.
Liao C, Zhao X, Brewer M, May V, Li J. Conformational transitions of the pituitary adenylate cyclase-activating polypeptide receptor, a human class B GPCR. Sci Rep Nat. 2017;7:5427.
Inooka H, Ohtaki T, Kitahara O, Ikegami T, Endo S, Kitada C, et al. Conformation of a peptide ligand bound to its G-protein coupled receptor. Nat Struct Mol Biol. 2001;8:161–5.
Dautzenberg M, Wille H. N-terminal splice variants of the Type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants. J Neuroendocrinol. 1999;11:941–9.
Otto C, Martin M, Paul Wolfer D, Lipp H-P, Maldonado R, Schütz G. Altered emotional behavior in PACAP-type-I-receptor-deficient mice. Mol Brain Res. 2001;92:78–84.
Li M, Shuto Y, Somogyvári-Vigh A, Arimura A. Prohormone convertases 1 and 2 process ProPACAP and generate matured, bioactive PACAP38 and PACAP27 in transfected rat pituitary GH4C1 cells. Neuroendocrinology. 1999;69:217–26.
Harakall SA, Brandenburg CA, Gilmartin GA, May V, Braas KM. Induction of multiple pituitary adenylate cyclase activating polypeptide (PACAP) transcripts through alternative cleavage and polyadenylation of proPACAP precursor mRNA. Ann N Y Acad Sci. 1998;865:367–74.
Fahrenkrug J, Buhl T, Hannibal J. PreproPACAP-derived peptides occur in VIP-producing tumours and co-exist with VIP. Regul Pept. 1995;58:89–98.
Hannibal J, Fahrenkrug J. Expression of pituitary adenylate cyclase activating polypeptide (PACAP) gene by rat spermatogenic cells. Regul Pept. 1995;55:111–5.
Tabuchi A, Koizumi M, Tsuda M. Novel splice variants of PACAP gene in mouse cerebellar granule cells. NeuroReport. 2001;12:1181.
Arimura A. Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research. Regul Pept. 1992;37:285–303.
Culler MD, Paschall CS. Pituitary adenylate cyclase-activating polypeptide (PACAP) potentiates the gonadotropin-releasing activity of luteinizing hormone-releasing hormone. Endocrinology. 1991;129:2260–2.
Suzuki Y, Kasai K, Takekoshi K, Oka M, Banba N, Numao T, et al. Effects of pituitary adenylate cyclase activating polypeptide (PACAP) on the cardiovascular system. Regul Pept. 1993;47:213–20.
Starr ER, Margiotta JF. PACAP Modulates distinct neuronal components to induce cell-specific plasticity at central and autonomic synapses. In: Reglődi D, Tamás A, editors. Pituitary Adenylate Cyclase Activating Polypeptide—PACAP [Internet]. Springer, Cham; 2016 [cited 2023 Jul 6]. p. 83–107. Available from: https://doi.org/10.1007/978-3-319-35135-3_7
Braas KM, May V, Harakall SA, Hardwick JC, Parsons RL. Pituitary adenylate cyclase-activating polypeptide expression and modulation of neuronal excitability in Guinea Pig cardiac ganglia. J Neurosci. 1998;18:9766–79.
Reglődi D, Tamás A, editors. Pituitary Adenylate Cyclase Activating Polypeptide—PACAP [Internet]. Springer, Cham; 2016 [cited 2023 Sep 27]. Available from: https://doi.org/10.1007/978-3-319-35135-3
Chamoux E, Breault L, LeHoux JG, Gallo-Payet N. Comparative effects of ACTH, PACAP, and VIP on fetal human adrenal cells. Endocr Res. 1998;24:943–6.
Kellogg DL, Zhao JL, Wu Y, Johnson JM. VIP/PACAP receptor mediation of cutaneous active vasodilation during heat stress in humans. J Appl Physiol. 2010;109:95–100.
Kellogg DL, Zhao JL, Wu Y, Johnson JM. Nitric oxide and receptors for VIP and PACAP in cutaneous active vasodilation during heat stress in humans. J Appl Physiol. 2012;113:1512–8.
Masmoudi-Kouki O, Gandolfo P, Castel H, Leprince J, Fournier A, Dejda A, et al. Role of PACAP and VIP in astroglial functions. Peptides. 2007;28:1753–60.
Reglődi D, Vaczy A, Rubio-Beltran E, MaassenVanDenBrink A. Protective effects of PACAP in ischemia. J Headache Pain. 2018;19:19.
Tamás A, Reglődi D, Farkas O, Kövesdi E, Pál J, Povlishock JT, et al. Effect of PACAP in central and peripheral nerve injuries. Int J Mol Sci. 2012;13:8430–48.
Kövesdi E, Tamás A, Reglődi D, Farkas O, Pál J, Tóth G, et al. Posttraumatic administration of pituitary adenylate cyclase activating polypeptide in central fluid percussion injury in rats. Neurotox Res. 2008;13:71–8.
Falluel-Morel A, Vaudry D, Aubert N, Galas L, Benard M, Basille M, et al. Pituitary adenylate cyclase-activating polypeptide prevents the effects of ceramides on migration, neurite outgrowth, and cytoskeleton remodeling. Proc Natl Acad Sci. 2005;102:2637–42.
Falluel-Morel A, Vaudry D, Aubert N, Galas L, Benard M, Basille M, et al. PACAP and ceramides exert opposite effects on migration, neurite outgrowth, and cytoskeleton remodeling. Ann N Y Acad Sci. 2006;1070:265–70.
Tóth D, Tamás A, Reglődi D. The neuroprotective and biomarker potential of PACAP in human traumatic brain injury. Int J Mol Sci. 2020;21:827.
Bukovics P, Czeiter E, Amrein K, Kovács N, Pál J, Tamás A, et al. Changes of PACAP level in cerebrospinal fluid and plasma of patients with severe traumatic brain injury. Peptides. 2014;60:18–22.
Reglődi D, Tamás A, Lengvári I, Tóth G, Szalontay L, Lubics A. Comparative study of the effects of PACAP in young, aging, and castrated males in a rat model of Parkinson’s disease. Ann N Y Acad Sci. 2006;1070:518–24.
Reglődi D, Kiss P, Lubics A, Tamás A. Review on the Protective Effects of PACAP in models of neurodegenerative diseases in vitro and in vivo. Curr Pharm Des. 2011;17:962–72.
Rat D, Schmitt U, Tippmann F, Dewachter I, Theunis C, Wieczerzak E, et al. Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer’s disease-like pathology in amyloid precursor protein-transgenic mice. FASEB J. 2011;25:3208–18.
Pinhasov A, Nesher E, Gross M, Turgeman G, Kreinin A, Yadid G. The role of the PACAP signaling system in depression. Curr Pharm Des. 2011;17:990–1001.
Hammack SE, Cheung J, Rhodes KM, Schutz KC, Falls WA, Braas KM, et al. Chronic stress increases pituitary adenylate cyclase-activating peptide (PACAP) and brain-derived neurotrophic factor (BDNF) mRNA expression in the bed nucleus of the stria terminalis (BNST): roles for PACAP in anxiety-like behavior. Psychoneuroendocrinology. 2009;34:833–43.
Spudich JA, Watt S. The regulation of rabbit skeletal muscle contraction. I. Biochemical studies of the interaction of the tropomyosin-troponin complex with actin and the proteolytic fragments of myosin. J Biol Chem. 1971;246:4866–71.
Víg AT, Földi I, Szikora S, Migh E, Gombos R, Tóth MÁ, et al. The activities of the C-terminal regions of the formin protein disheveled-associated activator of morphogenesis (DAAM) in actin dynamics. J Biol Chem. 2017;292:13566–83.
Tóth MÁ, Majoros AK, Vig AT, Migh E, Nyitrai M, Mihály J, et al. Biochemical activities of the Wiskott–Aldrich syndrome homology Region 2 domains of sarcomere length short (SALS) protein. J Biol Chem. 2016;291:667–80.
Lőrinczy D, Belágyi J. Scanning calorimetric and EPR studies on the thermal stability of actin. Thermochim Acta. 1995;259:153–64.
Jarry H, Leonhardt S, Schmidt WE, Creutzfeldt W, Wuttke W. Contrasting effects of pituitary adenylate cyclase activating polypeptide (PACAP) on in vivo and in vitro prolactin and growth hormone release in male rats. Life Sci. 1992;51:823–30.
Acknowledgements
This work was supported by CO-272 (OTKA) grant (DL) and supported by Hungarian Brain Research Program NAP 3.0, Thematic Excellence Program 2021 TKP2021-EGA-16, ELKH-TKI-14016, NKFIH K135457.
Funding
Open access funding provided by University of Pécs.
Author information
Authors and Affiliations
Contributions
PB is responsible for raising the problem, sample preparation and handling, data analysis, and manuscript writing. AT is responsible for financial support and supplying the PACAP for the study. DT is responsible for synthesis of PACAP fragments. DL is the corresponding author and principal investigator and is responsible for DSC experiments, data analysis, and manuscript writing.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Consent for publication
Copyright form has been uploaded with the manuscript.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Bukovics, P., Tamás, A., Tóth, G. et al. Investigating the impact of PACAP on thermal stability of G-actin by differential scanning calorimetry. J Therm Anal Calorim (2024). https://doi.org/10.1007/s10973-024-13289-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s10973-024-13289-z